Current management of inflammatory bowel disease.
Since the etiology and cure for inflammatory bowel disease remain elusive, treatment is still largely empiric. The major goals of therapy include control of bowel inflammation and alleviation of symptoms. Careful attention must be directed toward special problems when appropriate, such as short bowel syndrome, perianal disease, extraintestinal disease manifestations, and cancer surveillance. Standard and new forms of medical therapy and the approach to special problems will be discussed.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001372:Aza Compounds / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000628:therapy*; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008795:Metronidazole / Q000627:therapeutic use; D010347:Patient Care Planning; D012460:Sulfasalazine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D001372:Aza Compounds; D007166:Immunosuppressive Agents; D008795:Metronidazole; D012460:Sulfasalazine